BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28300829)

  • 21. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.
    Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
    Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
    Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
    Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The thioredoxin system in breast cancer cell invasion and migration.
    Bhatia M; McGrath KL; Di Trapani G; Charoentong P; Shah F; King MM; Clarke FM; Tonissen KF
    Redox Biol; 2016 Aug; 8():68-78. PubMed ID: 26760912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auranofin inhibits the occurrence of colorectal cancer by promoting mTOR-dependent autophagy and inhibiting epithelial-mesenchymal transformation.
    Zhang M; Yang DY; He ZY; Wu Y; Tian XY; Huang QY; Ma WB; Deng M; Wang QZ; Yan SJ; Zheng HL
    Anticancer Drugs; 2024 Feb; 35(2):129-139. PubMed ID: 37615540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.
    Sachweh MC; Stafford WC; Drummond CJ; McCarthy AR; Higgins M; Campbell J; Brodin B; Arnér ES; Laín S
    Oncotarget; 2015 Jun; 6(18):16488-506. PubMed ID: 26029997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Auranofin is a potent suppressor of osteosarcoma metastasis.
    Topkas E; Cai N; Cumming A; Hazar-Rethinam M; Gannon OM; Burgess M; Saunders NA; Endo-Munoz L
    Oncotarget; 2016 Jan; 7(1):831-44. PubMed ID: 26573231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species.
    Hwang-Bo H; Jeong JW; Han MH; Park C; Hong SH; Kim GY; Moon SK; Cheong J; Kim WJ; Yoo YH; Choi YH
    Gen Physiol Biophys; 2017 Apr; 36(2):117-128. PubMed ID: 28218611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.
    Hedström E; Eriksson S; Zawacka-Pankau J; Arnér ES; Selivanova G
    Cell Cycle; 2009 Nov; 8(21):3584-91. PubMed ID: 19838062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ROS-dependent activation of autophagy is a critical mechanism for the induction of anti-glioma effect of sanguinarine.
    Pallichankandy S; Rahman A; Thayyullathil F; Galadari S
    Free Radic Biol Med; 2015 Dec; 89():708-20. PubMed ID: 26472194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells.
    Wu P; Yu T; Wu J; Chen J
    Biomed Res Int; 2020; 2020():5875074. PubMed ID: 32596335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
    Kuo CC; Liu TW; Chen LT; Shiah HS; Wu CM; Cheng YT; Pan WY; Liu JF; Chen KL; Yang YN; Chen SN; Chang JY
    Free Radic Biol Med; 2011 Dec; 51(12):2195-209. PubMed ID: 22001324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
    Kiebala M; Skalska J; Casulo C; Brookes PS; Peterson DR; Hilchey SP; Dai Y; Grant S; Maggirwar SB; Bernstein SH
    Exp Hematol; 2015 Feb; 43(2):89-99. PubMed ID: 25448488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload.
    Harper MT
    Platelets; 2019; 30(1):98-104. PubMed ID: 29194002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma.
    Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
    Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
    Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation.
    Xie CM; Chan WY; Yu S; Zhao J; Cheng CH
    Free Radic Biol Med; 2011 Oct; 51(7):1365-75. PubMed ID: 21763418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldose Reductase Inhibitor Fidarestat as a Promising Drug Targeting Autophagy in Colorectal Carcinoma: a Pilot Study.
    Pandey S
    Asian Pac J Cancer Prev; 2015; 16(12):4981-5. PubMed ID: 26163626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
    Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
    Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.